Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B
Status:
Completed
Trial end date:
2010-09-16
Target enrollment:
Participant gender:
Summary
The "Chinese PAC" study (CLDT600ACN03) will evaluate the efficacy and safety of open label
telbivudine in 2,200 compensated Chronic Hepatitis B (CHB) adults. The primary objective of
the study is the proportion of patients achieving undetectable HBV DNA at week 52.